Emerging Therapies In Chronic Kidney Disease A Cross-Sectional Study

Abstract

Background:CKD is a highly prevalent ailment worldwide that is typified by gradual deterioration of kidney function and many complications. Just in the last decades, there has been progress in the management and the effectiveness of therapy with special reference to the pharmacological use.
Objectives: To assess the effectiveness of novel treatments and treatment strategies in CKD in terms of renal prognosis, cardiovascular risk and patients’ quality of life.
Study Desgin: A Cross-Sectional Study.
Place and Duration of study. January 2022 and july 2022 in a Urology MTI BKMC/MMC Mardan Pakistan
Methods: This study was a cross-sectional Study of 150 Patient with CKD at different stages of the disease. Participants were given conventional interventions with newly developed treatments such as SGLT2 inhibitors and fresh anti-inflammatory drugs. In the present study, we focused on collecting clinical data of the participants with eGFR, proteinuria and cardiovascular data over six months. Descriptive statistics using SD, comparison of the means and p-values for prevalence was used to determine the statistical significance for the data analyzed.
Results:SGLT2 inhibitors led to an enhancement of eGFR levels from 12% in 150 patients (mean age, 58.4 ± 6.2 years), (p < 0.01). The albuminuria was decreased over time in studied patient means 1.2 ± 0.4 g/day; p = 0.03; Experience of better cardiovascular result was observed. Renal benefits following the use of anti-inflammatory agents were subtle, hence figures were higher compared to placebo (p = 0.06).
Conclusion: antidiuretic drugs particularly SGLT2 inhibitors, have been shown to reduce CKD progression in patients with T2DM and, therefore, should play a vital function in CKD treatment. Further experimental studies will be important to determine ideal treatment approaches and other requirements still unmet.